Lifestyle change plus drugs may prevent MASLD in type 2 diabetes
Diabetes care and education specialists should identify people with diabetes at risk for metabolic dysfunction-associated steatotic liver disease and intervene early in disease progression, according to two speakers.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity for people with diabetes. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, professor emeritus at Midwestern University College of Pharmacy; diabetes care and education specialist and consultant at Bolingbrook Christian Health Center and Will Grundy Medical Clinic; and a Healio | Endocrine Today